Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target
$ORMP
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously